Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Serono
|
| gptkbp:division |
gptkb:Merck_KGaA
|
| gptkbp:focusArea |
neurology
oncology endocrinology fertility |
| gptkbp:founded |
2007
|
| gptkbp:headquartersLocation |
gptkb:Darmstadt,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Merck Serono
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:keyPerson |
gptkb:Belén_Garijo
Stefan Oschmann |
| gptkbp:mergedInto |
gptkb:Serono
|
| gptkbp:notable_drug |
gptkb:Erbitux
gptkb:Gonal-f gptkb:Rebif gptkb:Saizen gptkb:Cetrotide |
| gptkbp:numberOfEmployees |
~5,000 (as of 2020)
|
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Merck_KGaA
|
| gptkbp:predecessor |
gptkb:Serono
Merck KGaA Pharmaceuticals Division |
| gptkbp:products |
oncology drugs
biopharmaceuticals fertility treatments multiple sclerosis treatments |
| gptkbp:website |
https://www.merckserono.com/
|
| gptkbp:bfsParent |
gptkb:Gonal-f
gptkb:Saizen gptkb:Cetrotide gptkb:Crinone gptkb:Luveris gptkb:Pergoveris |
| gptkbp:bfsLayer |
6
|